In another profiling study, miR-181b has been identified as a regulator of NF-κB signaling and a potential therapeutic target, while miR-125b and miR-155 hold promise as biomarkers for distinguishing CRS subtypes [48]. Here, NFKB1 is linked to congenital rubella syndrome.